Embecta (NASDAQ:EMBC) Insider Jeffrey Mann Acquires 20,000 Shares

Embecta Corp. (NASDAQ:EMBC) insider Jeffrey Mann acquired 20,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $4.99 per share, with a total value of $99,800.00. Following the completion of the purchase, the insider owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This trade represents a 8.23% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Embecta Stock Performance

NASDAQ EMBC opened at $5.11 on Friday. Embecta Corp. has a one year low of $2.77 and a one year high of $15.55. The company has a market capitalization of $289.53 million, a price-to-earnings ratio of 3.45 and a beta of 0.81. The company’s 50-day simple moving average is $3.46 and its two-hundred day simple moving average is $6.42.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.29. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. During the same quarter in the prior year, the company earned $1.12 EPS. The company’s revenue was down 8.1% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Equities analysts expect that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Embecta Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be issued a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is currently 2.70%.

Analyst Ratings Changes

A number of research firms recently commented on EMBC. Mizuho decreased their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Wall Street Zen lowered Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Bank of America lowered their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday, May 18th. Finally, BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $11.00.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively bought 70,000 Embecta shares worth approximately $334,200 on August 12. The purchases increased their individual holdings and may signal management confidence that the stock is undervalued. SEC insider transaction filing
• Neutral Sentiment: Several investor-rights firms are reminding shareholders that August 17, 2026, is the deadline to seek appointment as lead plaintiff for investors who purchased EMBC shares between November 25, 2025, and May 4, 2026. These announcements largely repeat the same lawsuit information rather than represent new company operating news. BFA Law class action reminder
• Negative Sentiment: The filed class action alleges that Embecta and certain executives violated federal securities laws by misrepresenting the commercial stability of its insulin pen-needle business and issuing misleading fiscal 2026 guidance. The claims follow a significant stock decline and could create legal costs, reputational damage and additional uncertainty around management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert

Institutional Trading of Embecta

A number of institutional investors have recently bought and sold shares of EMBC. SG Americas Securities LLC raised its holdings in shares of Embecta by 138.4% in the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock worth $9,184,000 after buying an additional 603,106 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Embecta during the first quarter valued at $7,013,000. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Embecta by 1,068.0% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 143,616 shares of the company’s stock valued at $1,708,000 after acquiring an additional 131,320 shares during the period. UBS Group AG increased its position in shares of Embecta by 200.8% in the 4th quarter. UBS Group AG now owns 630,994 shares of the company’s stock valued at $7,496,000 after acquiring an additional 421,254 shares during the period. Finally, LSV Asset Management raised its stake in Embecta by 92.5% in the 4th quarter. LSV Asset Management now owns 552,582 shares of the company’s stock worth $6,565,000 after acquiring an additional 265,482 shares during the last quarter. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.